Device Trial Radar · NCT03228420
Comparison of 10 kHz SCS Combined With CMM to CMM Alone in the Treatment of Neuropathic Limb Pain
Last checked: Nov 20, 2026Latest source record: Jul 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
430
Actual
Start
Jul 20, 2017
Primary completion
May 1, 2020
Study completion Nov 28, 2022
Sponsor
- Lead sponsor
- Nevro CorpNot on our public-company list
- Sponsor type
- Industry
- First posted
- Jul 24, 2017
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 22 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This post-market study is being conducted to document comparative safety, clinical effectiveness, and cost-effectiveness of the addition of HF10™ therapy to CMM compared with CMM alone in subjects with chronic, intractable, neuropathic lower limb pain due to diabetic neuropathy (Painful Diabetic Neuropathy or PDN). This study is a multi-center, prospective, randomized comparison of the two treatments.
Conditions
- Painful Diabetic Neuropathy
Interventions
Senza HF10 TherapyDevice
Senza 10kHz Spinal Cord Stimulation
CMMOther
Conventional Medical Management
Primary outcomes
What the sponsor says the trial is designed to measure.
- Composite of Safety and EffectivenessTime frame: 3 months
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Coastal Orthopedics
Bradenton, Florida
Georgia Pain Care
Stockbridge, Georgia
Duke University Medical Center
Durham, North Carolina
1 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.